Evidence map›Paper›PMID 36894193›Full record

ArticleRMD open2023

Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.

Alexis F Guedon, Laure Ricard, Charlotte Laurent, Claire De Moreuil, Geoffrey Urbanski, Sophie Deriaz, Grigorios Gerotziafas, Ismail Elalamy, Alexandra Audemard, Francois Chasset and 9 more

Abstract readMulticenter Study
In one paragraph

Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Review
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alexis F GuedonSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.ORCID 0000-0002-4571-6219
Laure RicardSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
Charlotte LaurentSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
Claire De MoreuilService de Médecine Interne, CHRU de Brest, Brest, France.
Geoffrey UrbanskiService de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.
Sophie DeriazService de Médecine Interne, CHRU et université de Tours, Tours, France.
Grigorios GerotziafasService de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
Ismail ElalamyService de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
Alexandra AudemardService de Médecine Interne, CHRU et université de Tours, Tours, France.
Francois ChassetService de Dermatologie et Vénérologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
Sonia AlamowitchService des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpétrière, AP-HP, Centre de Recherche de Saint Antoine, INSERM, UMRS 938, Sorbonne Université Paris, Paris, France.
Jérémie SellamService de Rhumatologie, CRSA INSERM, UMRS 938, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
Jean Jacques BoffaService de Néphrologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
Ariel CohenService de Cardiologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
Clémentine WahlSorbonne Université, Service d'hématologie biologique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Noemie AbisrorSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
François MaillotService de Médecine Interne, CHRU et université de Tours, Tours, France.
Olivier FainSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
Arsène MekinianSorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France arsene.mekinian@aphp.fr.ORCID 0000-0003-2849-3049

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (arterial, venous or small vessel) or obstetrical events and persistent antiphospholipid antibodies (aPL), according to the Sydney classification criteria. Many studies have performed cluster analyses among patients with primary APS and associated autoimmune disease, but none has focused solely on primary APS. We aimed to perform a cluster analysis among patients with primary APS and asymptomatic aPL carriers without any autoimmune disease, to assess prognostic value.

methodsIn this multicentre French cohort study, we included all patients with persistent APS antibodies (Sydney criteria) measured between January 2012 and January 2019. We excluded all patients with systemic lupus erythematosus or other systemic autoimmune diseases. We performed hierarchical cluster analysis on the factor analysis of mixed data coordinates results with baseline patient characteristics to generate clusters.

resultsWe identified four clusters: cluster 1, comprising 'asymptomatic aPL carriers', with low risk of events during follow-up; cluster 2, the 'male thrombotic phenotype', with older patients and more venous thromboembolic events; cluster 3, the 'female obstetrical phenotype', with obstetrical and thrombotic events; and cluster 4, 'high-risk APS', which included younger patients with more frequent triple positivity, antinuclear antibodies, non-criteria manifestations and arterial events. Regarding survival analyses, asymptomatic aPL carriers relapsed less frequently than the others, but no other differences in terms of relapse rates or deaths were found between clusters.

conclusionsWe identified four clusters among patients with primary APS, one of which was 'high-risk APS'. Clustering-based treatment strategies should be explored in future prospective studies.

Indexed as

Antiphospholipid SyndromeAutoimmune DiseasesLupus Erythematosus, SystemicThrombosisAntibodies, AntiphospholipidCohort StudiesFemaleHumansMaleAntibodies, AntiphospholipidAntiphospholipid SyndromeAutoimmune DiseasesLupus Erythematosus, Systemic

Identifiers

PMID36894193
PMCPMC10008476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.